A phase 3 randomised, double-blind study of Nivolumab or Placebo in combination with Doctaxel, in men with metastatic castration-resistant Prostate Cancer (CheckMate 7DX: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 7DX).

  • Pook, David (Primary Chief Investigator (PCI))
  • Baker, Emma (Project Manager)

Project: Research

Project Details

Effective start/end date27/04/2031/12/23


  • Prostrate Cancer
  • Clinical trial